Sorrect Sequence
Latest round
- Series A
Last raised
- Aug 2024
Total raised
- $67M
Investors
- 7
About Sorrect Sequence
Established in 2020 and based in Shanghai, China, Sorrect Sequence is a gene technology developer that focuses on the research and development of gene editing technology. The company was co-founded by Prof. Jia Chen, Prof. Li Yang, Prof. Hao Yin, and Prof. Beiyang. The company is headquartered in Shanghai, with R&D and manufacturing centers in Shanghai and a clinical registration and operations center in Beijing.D.S. and has nearly 20 years of experience in CMC process development for antibodies and fusion proteins. The company's self-developed CS-101 injectable drug was approved in April 2024 for IND. The company's business is the research and development of innovative gene editing therapies. The company's self-developed core product is the Translational Gene Editor tBE (Transformer Base Editor). Its products are used in the fields of genetic, metabolic and cardiovascular diseases. Sorrect Sequence generates revenue by offering licensing agreements for its proprietary gene editing technology, conducting collaborative research with pharmaceutical partners, and driving the commercialization of its therapies through clinical trials.
Who invested in Sorrect Sequence
7 investors across 3 rounds
See all investors in Sorrect Sequence
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sorrect Sequence
Who invested in Sorrect Sequence?
Sorrect Sequence has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sorrect Sequence raised?
Sorrect Sequence has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Sorrect Sequence last raise money?
Sorrect Sequence's most recent round on record is a Series A, in Aug 2024.
What does Sorrect Sequence do?
Established in 2020 and based in Shanghai, China, Sorrect Sequence is a gene technology developer that focuses on the research and development of gene editing technology.
Where is Sorrect Sequence headquartered?
Sorrect Sequence is headquartered in Shanghai, China.
Which VCs invest in companies like Sorrect Sequence?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Sorrect Sequence's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Sorrect Sequence? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.